Pfizer discontinues GLP-1 pill trial, stock trades flat [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
A trial participant in the phase III trial of its once-daily pill experienced "potential drug-induced liver injury" that disappeared after the participant stopped the pill, the company said in a statement. "While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients," Pfizer chief scientific officer Chris Boshoff said. The company had hoped to compete in the obesity space and had been optimistic in recent public statements about the potential of danuglipron. This is the latest disappointment in what has been a bumpy ride in Pfizer's attempt to enter the hot obesity market and compete with market leaders Eli Lilly ( LLY ) and Novo Nordisk ( NVO ). It previously had a twice-daily pill that was also scrapped after similar liver concerns in 2023 The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- 5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 [Yahoo! Finance]Yahoo! Finance
- BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator [Yahoo! Finance]Yahoo! Finance
- Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing [Yahoo! Finance]Yahoo! Finance
- These people lost their sense of taste. Are GLP-1s to blame? [USA TODAY]USA TODAY
- Healthcare Stocks: Outlook For 2026 [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website